There are several interactions within the tumor microenvironment (TME) that affect the
response of cancer cells to therapy. There are also a large number of cells and secretions in …

Abstract Purpose of Review Immune checkpoint inhibitors (ICIs) have improved the field of
cancer, especially in patients with advanced malignancies. Nevertheless, cardiovascular …

Background Lung adenocarcinoma (LUAD) kills millions of people every year. Recently,
FDA and researchers proved the significance of high tumor mutational burden (TMB) in …

Background Previous studies revealed that Programmed cell death protein 1 (PD-
1)/Programmed cell death-Ligand protein 1 (PD-L1) inhibitors plus anti-angiogenic agents …

Background: Genomic instability is increased alterations in the genome during cell division
and is common among most cancer cells. Genome instability enhances the risk of initial …

Outcome improvement in patients with driver-gene-negative advanced non-small cell lung
cancer (NSCLC) has been significantly enhanced through targeting the immune system …

Background Despite the fact that numerous clinical and preclinical studies have
demonstrated the synergistic effects of combining antiangiogenic or chemotherapy with …

Abstract Introduction Programmed death 1 (PD-1)/programmed death 1 ligand 1 (PD-L1)-
directed immunotherapy has revolutionized the treatments for advanced non-small cell lung …

Background The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in
treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who …

Background The use of immune checkpoint inhibitors (ICIs) for the treatment of lung cancer
may precipitate cardiotoxic events. We aimed to perform a meta-analysis to evaluate the …